Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.00
- Piotroski Score 6.00
- Grade Hold
- Symbol (PROC)
- Company Procaps Group S.A.
- Price $2.20
- Changes Percentage (-1.76%)
- Change -$0.04
- Day Low $2.20
- Day High $2.20
- Year High $4.95
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products. In addition, the company offers over-the-counter (OTC) consumer healthcare products through a portfolio on approximately eight therapeutic areas, including gastrointestinal, skin care, cough and cold, analgesics, urological, vitamins, minerals, and supplements in the categories of antibiotics, anti-infective, anti-parasitic, cardiovascular, feminine care, cutaneous antimycotic, pain killers, gastro intestinal, hormonals, metabolic, endocrine, nervous system, ophthalmic, osteoarticular, respiratory, diet supplements, and vitamins and minerals. Further, it provides blood glucose meters, telemonitoring products, oral anti-diabetics products, cosmeceuticals, insulin delivery systems, and other diabetes solutions; and contract drug development and manufacturing services to third party pharmaceutical companies, specializing in soft gelatin capsule technologies. The company was founded in 1977 and is based in Luxembourg, Luxembourg.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/13/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $10.00
- Low Stock Price Target $10.00
- Potential Upside/Downside N/A
- Consensus Rating Neutral
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) $0.51
- Trailing P/E Ratio 5.16
- Forward P/E Ratio 5.16
- P/E Growth 5.16
- Net Income $42.54 M
Income Statement
Quarterly
Annual
Latest News of PROC
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Are Lower Interest Rates to Blame for Knocking Dividend Kings Coca-Cola and Procter & Gamble Off Their All-Time Highs?
Coca-Cola and Procter & Gamble are established Dividend Kings with over 60 years of dividend increases. Both being components of the Dow Jones, they offer steady performance regardless of economic cyc...
By Yahoo! Finance | 1 day ago -
Jim Cramer Prefers Intuitive Surgical, Inc. (NASDAQ:ISRG) Over Procept Biorobotics
A recent list of Jim Cramer Stock Portfolio for Q4 highlights Intuitive Surgical, Inc. as a top choice. Cramer advises taking profits during stock rallies and recommends ISRG over Procept Biorobotics....
By Yahoo! Finance | 2 days ago -
49ers' Samuel, Kittle trending toward playing vs. Patriots; Christian McCaffrey ramping up rehab process
San Francisco's injury report for Week 3 shows Samuel likely to return from a calf injury, while Kittle and Purdy are fully practicing. McCaffrey's recovery involves rest for his Achilles, with plans ...
By The New York Times | 3 days ago
